Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 1/2004

01.07.2004 | Original Article

Induction of histone acetylation and inhibition of growth by phenyl alkanoic acids and structurally related molecules

verfasst von: Michael A. Lea, Asif Shareef, Monali Sura, Charles desBordes

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2004

Einloggen, um Zugang zu erhalten

Abstract

Purpose

A structure-activity study was undertaken to determine the influence of side chain length of phenyl alkanoic acids and the degree of unsaturation of phenyl alkenoic acids on the induction of histone acetylation and inhibition of cancer cell proliferation.

Materials and methods

Studies on cell proliferation were performed with DS19 mouse erythroleukemic cells, PC-3 human prostate cancer cells and Caco-2 human colon cancer cells. Actions on histone deacetylase and the induction of histone acetylation were compared for 4-phenylbutyrate and structurally related molecules.

Results

Increasing inhibition of cell proliferation by phenyl alkanoic acids together with a decrease in cells in S phase and an increase in apoptotic cells was observed with increased chain length between four and ten carbons. Introduction of double bonds into the side chain was associated with increased growth inhibition. In contrast, 4-phenylbutyrate was a more potent inhibitor of histone deacetylase and inducer of histone acetylation than the other phenyl alkanoic acids examined.

Conclusions

In comparison with the action of 4-phenylbutyrate, actions other than inhibition of histone deacetylase appear to be more important for growth inhibition by longer chain phenyl alkanoic and phenyl alkenoic acids.
Literatur
1.
Zurück zum Zitat Boffa LC, Vidali G, Mann RS, Allfrey VG (1978) Suppression of histone deacetylation in vivo and in vitro by sodium butyrate J Biol Chem 253:3364 Boffa LC, Vidali G, Mann RS, Allfrey VG (1978) Suppression of histone deacetylation in vivo and in vitro by sodium butyrate J Biol Chem 253:3364
2.
Zurück zum Zitat Carducci MA, Nelson JB, Chan-Tack KM, Ayyagari SR, Sweatt WH, Campbell PA, Nelson WG, Simons JW (1996) Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Res 2:379 Carducci MA, Nelson JB, Chan-Tack KM, Ayyagari SR, Sweatt WH, Campbell PA, Nelson WG, Simons JW (1996) Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Res 2:379
3.
Zurück zum Zitat Chang T-H, Szabo E (2002) Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-γ and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res 8:1206PubMed Chang T-H, Szabo E (2002) Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-γ and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res 8:1206PubMed
4.
Zurück zum Zitat Clarke KO, Ludeman SM, Springer JB, Colvin OM, Lea MA, Harrison LE, (2002) Exposure to a deuterated analogue of phenylbutyrate retards S phase progression in HT-29 colon cancer cells. J Pharm Sci 91:1054CrossRefPubMed Clarke KO, Ludeman SM, Springer JB, Colvin OM, Lea MA, Harrison LE, (2002) Exposure to a deuterated analogue of phenylbutyrate retards S phase progression in HT-29 colon cancer cells. J Pharm Sci 91:1054CrossRefPubMed
5.
Zurück zum Zitat Fajas L, Egler V, Reiter R, Hansen J, Kristiansen K, Debril MB, Miard S, Auwerx J (2002) The retinoblastoma-histone deacetylase 3 complex inhibits PPARγ and adipocyte differentiation. Dev Cell 3:903PubMed Fajas L, Egler V, Reiter R, Hansen J, Kristiansen K, Debril MB, Miard S, Auwerx J (2002) The retinoblastoma-histone deacetylase 3 complex inhibits PPARγ and adipocyte differentiation. Dev Cell 3:903PubMed
6.
Zurück zum Zitat Feinman R, Clarke KO, Harrison LE (2002) Phenylbutyrate-induced apoptosis is associated with inactivation of NF-κB in HT-29 colon cancer cells. Cancer Chemother Pharmacol 49:27CrossRefPubMed Feinman R, Clarke KO, Harrison LE (2002) Phenylbutyrate-induced apoptosis is associated with inactivation of NF-κB in HT-29 colon cancer cells. Cancer Chemother Pharmacol 49:27CrossRefPubMed
7.
Zurück zum Zitat Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA (2001) A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7:2292PubMed Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA (2001) A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7:2292PubMed
8.
Zurück zum Zitat Gore SD, Carducci MA (2000) Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Exp Opin Invest Drugs 9:2923 Gore SD, Carducci MA (2000) Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Exp Opin Invest Drugs 9:2923
9.
Zurück zum Zitat Gore SD, Weng L-J, Figg WD, Zhai SZ, Donehower RC, Dover G, Grever MR, Griffin C, Grochow LB, Hawkins A, Burks, K, Zabelena Y, Miller CB (2002) Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 8:963PubMed Gore SD, Weng L-J, Figg WD, Zhai SZ, Donehower RC, Dover G, Grever MR, Griffin C, Grochow LB, Hawkins A, Burks, K, Zabelena Y, Miller CB (2002) Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 8:963PubMed
10.
Zurück zum Zitat Houseknecht KL, Cole BM, Steele PJ (2002) Peroxisome proliferator-activated receptor gamma (PPARγ) and its ligands: a review. Domestic Animal Endocrinol 22:1CrossRef Houseknecht KL, Cole BM, Steele PJ (2002) Peroxisome proliferator-activated receptor gamma (PPARγ) and its ligands: a review. Domestic Animal Endocrinol 22:1CrossRef
11.
Zurück zum Zitat Hruban Z, Morris HP, Mochizuki Y, Meranze DR, Slesers A (1971) Light microscopic observations of Morris hepatomas. Cancer Res 31:752PubMed Hruban Z, Morris HP, Mochizuki Y, Meranze DR, Slesers A (1971) Light microscopic observations of Morris hepatomas. Cancer Res 31:752PubMed
12.
Zurück zum Zitat Jung M (2001) Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem 8:1505PubMed Jung M (2001) Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem 8:1505PubMed
13.
Zurück zum Zitat Krämer OH, Göttlicher M, Heinzel T (2001) Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 12:294 Krämer OH, Göttlicher M, Heinzel T (2001) Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 12:294
14.
Zurück zum Zitat Lea MA, Randolph VM (1998) Induction of reporter gene expression by inhibitors of histone deacetylase. Anticancer Res 18:2717PubMed Lea MA, Randolph VM (1998) Induction of reporter gene expression by inhibitors of histone deacetylase. Anticancer Res 18:2717PubMed
15.
Zurück zum Zitat Lea MA, Tulsyan N (1995) Discordant effects of butyrate analogues on erythroleukemia cell proliferation and histone deacetylase. Anticancer Res 15:879PubMed Lea MA, Tulsyan N (1995) Discordant effects of butyrate analogues on erythroleukemia cell proliferation and histone deacetylase. Anticancer Res 15:879PubMed
16.
Zurück zum Zitat Lea MA, Randolph VM, Hodge SK (1999) Induction of histone acetylation and growth regulation in erythroleukemia cells by 4-phenylbutyrate and structural analogs. Anticancer Res 19:1971PubMed Lea MA, Randolph VM, Hodge SK (1999) Induction of histone acetylation and growth regulation in erythroleukemia cells by 4-phenylbutyrate and structural analogs. Anticancer Res 19:1971PubMed
17.
Zurück zum Zitat Lea MA, Rasheed M, Randolph VM, Khan F, Shareef A, desBordes C (2002) Induction of histone acetylation and inhibition of growth of mouse erythroleukemia cells by S-allylmercaptocysteine. Nutr Cancer 43:90CrossRefPubMed Lea MA, Rasheed M, Randolph VM, Khan F, Shareef A, desBordes C (2002) Induction of histone acetylation and inhibition of growth of mouse erythroleukemia cells by S-allylmercaptocysteine. Nutr Cancer 43:90CrossRefPubMed
18.
Zurück zum Zitat Lea MA, Shareef A, desBordes C (2003) Actions other than inhibition of histone deacetylase may be more important for growth inhibition by some phenyl alkanoic and phenyl alkenoic acids. Proc Am Assoc Cancer Res 44 (2nd edn), 1315 Lea MA, Shareef A, desBordes C (2003) Actions other than inhibition of histone deacetylase may be more important for growth inhibition by some phenyl alkanoic and phenyl alkenoic acids. Proc Am Assoc Cancer Res 44 (2nd edn), 1315
19.
Zurück zum Zitat Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194CrossRefPubMed Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194CrossRefPubMed
20.
Zurück zum Zitat Melchior SW, Brown LG, Figg WD, Quinn JA, Santucci RA, Brunner J, Thüroff JW, Lange PH, Vessella RL (1999) Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo. Int J Oncol 14:501PubMed Melchior SW, Brown LG, Figg WD, Quinn JA, Santucci RA, Brunner J, Thüroff JW, Lange PH, Vessella RL (1999) Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo. Int J Oncol 14:501PubMed
21.
Zurück zum Zitat Morris HP, Meranze DR (1974) Induction and some characteristics of “minimal deviation” and other transplantable rat hepatomas. Recent Results Cancer Res 44:102 Morris HP, Meranze DR (1974) Induction and some characteristics of “minimal deviation” and other transplantable rat hepatomas. Recent Results Cancer Res 44:102
22.
Zurück zum Zitat Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA (2001) Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 61:1477PubMed Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA (2001) Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 61:1477PubMed
23.
Zurück zum Zitat Pineau T, Hudgins WR, Liu L, Chen L-C, Sher T, Gonzalez FJ, Samid D (1996) Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem Pharmacol 52:659PubMed Pineau T, Hudgins WR, Liu L, Chen L-C, Sher T, Gonzalez FJ, Samid D (1996) Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem Pharmacol 52:659PubMed
24.
Zurück zum Zitat Reeves R, Candido EPM (1978) Turnover of histone acetyl groups in cultured cells is inhibited by sodium butyrate. FEBS Lett 91:117CrossRefPubMed Reeves R, Candido EPM (1978) Turnover of histone acetyl groups in cultured cells is inhibited by sodium butyrate. FEBS Lett 91:117CrossRefPubMed
25.
Zurück zum Zitat Rosen ED, Spiegelman BM (2001) PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276:37731PubMed Rosen ED, Spiegelman BM (2001) PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276:37731PubMed
26.
Zurück zum Zitat Samid D, Wells M, Greene ME, Shen W, Palmer CAN, Thibault A (2000) Peroxisome proliferator-activated receptor γ as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity. Clin Cancer Res 6:933PubMed Samid D, Wells M, Greene ME, Shen W, Palmer CAN, Thibault A (2000) Peroxisome proliferator-activated receptor γ as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity. Clin Cancer Res 6:933PubMed
27.
Zurück zum Zitat Sealy L, Chalkley R (1978) The effect of sodium butyrate on histone modification. Cell 14:115PubMed Sealy L, Chalkley R (1978) The effect of sodium butyrate on histone modification. Cell 14:115PubMed
28.
Zurück zum Zitat Warrell RP, He L-Z, Richon V, Calleja E, Pandolfi PP (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90:1621PubMed Warrell RP, He L-Z, Richon V, Calleja E, Pandolfi PP (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90:1621PubMed
29.
Zurück zum Zitat Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S (2001) Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 48:S20CrossRefPubMed Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S (2001) Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 48:S20CrossRefPubMed
Metadaten
Titel
Induction of histone acetylation and inhibition of growth by phenyl alkanoic acids and structurally related molecules
verfasst von
Michael A. Lea
Asif Shareef
Monali Sura
Charles desBordes
Publikationsdatum
01.07.2004
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 1/2004
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-004-0782-5

Weitere Artikel der Ausgabe 1/2004

Cancer Chemotherapy and Pharmacology 1/2004 Zur Ausgabe

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.